| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Arrowhead Pharma (NASDAQ:ARWR) reported its Q1 earnings results on Tuesday, February 6, 2024 at 04:01 PM.
Here's what investors need to know about the announcement.
Arrowhead Pharma missed estimated earnings by 51.22%, reporting an EPS of $-1.24 versus an estimate of $-0.82.
Revenue was down $58.99 million from the same period last year.
Last quarter the company missed on EPS by $0.42 which was followed by a 26.85% drop in the share price the next day.
Here's a look at Arrowhead Pharma's past performance:
| Quarter | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|
| EPS Estimate | -0.60 | -0.58 | -0.64 | 0.44 |
| EPS Actual | -1.02 | -0.96 | 0.45 | -0.39 |
| Revenue Estimate | 50.73M | 48.19M | 45.48M | 162.52M |
| Revenue Actual | 16.10M | 15.82M | 146.27M | 62.55M |
To track all earnings releases for Arrowhead Pharma visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: ARWR
